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Abstract
Background: The epidermal growth factor receptor monoclonal antibody cetuximab has proven activity in
metastatic colorectal cancer. To date, the mechanisms of action are not completely understood. Especially the
impact on tumor glucose metabolism, or tumor vascularization remains largely unclear. The understanding of
mechanisms such as early changes in tumor metabolism is of clinical importance since there may be a substantial
influence on choice and sequence of drug combinations. Early signals of response to cetuximab may prove useful
to identify patients having a relevant clinical treatment benefit. The objective of this trial is to evaluate the
predictive relevance of the relative change in
18 F-Fluorodeoxyglucose tumor uptake for early clinical response
during short-term single agent treatment with cetuximab. Early clinical response will be routinely measured
according to the response evaluation criteria in solid tumors. Accompanying research includes cytokine immune
monitoring and analysis of tumor proteins and tumor genes.
Methods/design: The REMOTUX trial is an investigator-initiated, prospective, open-label, single-arm, single-center
early exploratory predictive study. The first
18 F-FDG PET-CT is conducted at baseline followed by the run-in phase
with cetuximab at days 1 and 8. At day 14, the second
18 F-FDG PET-CT is performed. Subsequently, patients are
treated according to the Folfiri-cetuximab regimen as an active and approved first-line regimen for metastatic
colorectal carcinoma. At day 56, clinical response is evaluated with a CT-scan compared to the baseline analysis.
Tracer uptake is assessed using standardized uptake values (SUVs). The main hypothesis to be tested in the primary
analysis is whether or not the relative change in the SUV from baseline to day 14 has any predictive relevance for
early clinical response determined at day 56. Patients are followed until death from any cause or until 24 months
after the last patient has ended trial treatment.
Discussion: The aim of this trial is to evaluate metabolic changes in metastatic colorectal cancer during short-term
single agent treatment with cetuximab and to analyse their potential of predicting early clinical response. This
could be helpful to answer the question if early identification of patients not responding to cetuximab is possible.
Trial registration: ClinicalTrials.gov NCT200811021020; EudraCT 200901327923
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Colorectal cancer is one of the three most common
types of cancer in men and in women. It is estimated
that about 1.2 million new cases were diagnosed world-
wide in 2008 and approximately 609.000 deaths
occurred [1]. The 5-year overall survival rate for patients
with metastatic disease in the western world has
increased during the last decade and is nowadays
reported to reach about 10% [1]. The median overall
survival for patients treated with active combination
chemotherapies and monoclonal antibodies (mABs) is
nowadays in excess of two years [2].
The epidermal growth factor receptor (EGFR) mAB
cetuximab has proven activity in metastatic colorectal
cancer. In combination with an irinotecan-containing
cytotoxic regimen (Folfiri), cetuximab significantly
increases progression free survivial (PFS) in first-line
therapy compared to the Folfiri regimen alone [3]. In
patients with metastatic colorectal cancer that no longer
respond to previous chemotherapy for advanced disease,
cetuximab significantly improves overall survival (OS)
and PFS compared to best supportive care alone [4].
More recently, it has been demonstrated that efficacy of
cetuximab is significantly associated with a wild-type
KRAS status [5,6]. Cetuximab is approved by the Eur-
opean Medicines Agency (EMEA) for the treatment of
patients with EGFR expressing, KRAS wild-type meta-
static colorectal cancer (in combination with chemother-
apy as well as single-agent-therapy in patients who have
failed oxaliplatin- and irinotecan-based therapy and who
are intolerant to irinotecan). Nevertheless, there is still a
group of patients with wild-type KRAS status that does
not benefit from treatment with cetuximab, and addi-
tional mechanisms of resistance are assumed. Despite all
advances, it is yet not possible to identify patients who
will respond to cetuximab treatment upfront. Given the
substantial therapy costs and the considerable rate of side
effects (especially skin toxicity), improved strategies for
identifying responders are needed. Patients who are
responsive to cetuximab treatment may gain a tremen-
dous benefit if combinations of chemotherapy and cetux-
imab are given in the first-line situation, because a switch
from primarily palliative chemotherapeutic treatment to
a curative surgical approach („conversion therapy”)
s e e m st ob em o r ep r e v a l e n ti np a t i e n t sw h oa r er e s p o n -
sive to induction treatment [7].
To date, the influence of cetuximab on tumor glucose
metabolism, tumor vascularization and angiogenesis
remains largely unclear. The understanding of these pro-
cesses such as early changes in tumor glucose uptake or
changes in blood flow parameters is of utmost clinical
interest since early signals of response to cetuximab may
prove useful to identify those patients who have a rele-
vant clinical benefit from treatment. In general, the role
of metabolic imaging and early response assessment to
anticancer therapy is one of oncology’s key questions
today. The implications for therapeutic management and
treatment strategies, especially in patients with gastroin-
testinal cancer, are a point of intensive discussion [8]. For
example, in locally advanced adenocarcinoma of the eso-
phagogastric junction, the MUNICON trial showed the
value of early metabolic response evaluation and demon-
strated the feasibility of a PET-guided treatment algo-
rithm in clinical practice [9]. The potential of sequential
18 F-FDG PET (18 F-Fluorodeoxyglucose positron emis-
sion tomography) in patients with adenocarcinoma of the
esophagogastric junction under salvage radiotherapy is
actually investigated by the HICON trial [10]. Referring
to
18 F-FDG PET, changes of the standardized uptake
value (SUV) rather than the absolute SUV values are con-
sidered to be the most reliable parameter for therapeutic
response assessment [11].
The primary objective of the REMOTUX trial (in vivo
response monitoring of treatment with the EGFR-mAB
cetuximab in metastatic colorectal cancer)i st oe v a l u a t e
the predictive relevance of the change in
18 F-FDG tumor
uptake during short-term run-in treatment with cetuxi-
mab for the early clinical tumor response, determined
according to the response evaluation criteria in solid
tumors (RECIST) [12] after sequential Folfiri-cetuximab
therapy. Antivascular and/or antiangiogeneic effects of
cetuximab by contrast-enhanced ultrasound will also be
assessed in the secondary analysis. An accompanying
translational research programm analyses EGFR depen-
dent signaling pathways and immunological parameters
influenced by cetuximab.
Methods/design
Ethical and legal considerations
The REMOTUX study protocol, the patient information
and informed consent sheets for study participation
and additional translational research were approved
by the local ethics committee at the University of
Heidelberg. Additionally, the study was authorised by
the Paul-Ehrlich-Institut (as an agency of the German
Federal Ministry of Health) and by the German Federal
Authorities for Radiation Protection (Bundesamt für
Strahlenschutz) according to federal law. The trial is
registered at the ClinicalTrials.gov protocol registration
system (identification code NCT200811021020) and the
EudraCT register (identification code 200901327923).
All patients provide written informed consent before
study inclusion. A patient may be withdrawn from the
trial treatment at any time at his own request
Study design and treatment schedule
The REMOTUX trial is designed and conducted at
the National Center for Tumor disease (NCT) at the
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tor-initiated, prospective, open-label, single-arm, and
single-center early exploratory predictive study.
The first
18 F-FDG PET-CT (and liver ultrasound, if
available), is conducted at baseline followed by the run-in
treatment phase with cetuximab therapy at days 1 and 8
(400 mg/m
2 bsa and 250 mg mg/m
2 bsa respectively). At
day 14, the second
18 F-FDG PET-CT (and liver ultra-
sound, if available) is performed. Subsequently, patients
are treated according to the Folfiri-cetuximab regimen as
an active and approved first-line regimen for metastatic
colorectal carcinoma. According to the clinical standards
at the NCT Heidelberg, the Folfiri-cetuximab regimen is
recommended to follow the schedule of Table 1. At day
56, the early clinical response is evaluated with a routine
CT-scan in comparison to the baseline analysis. Depend-
ing on the clinical response, treatment will be continued
according to the choice of the responsible physician. It is
recommended that, in case of response, treatment will be
continued with cetuximab and the Folfiri regimen until
disease progression or patients are unable to tolerate the
therapy. Patients are followed-up every 3 months. Patients
are followed until death from any cause or until 24 months
after the last patient has ended trial treatment. A flowchart
is given in Table 2.
Diagnostic procedures
18F-FDG PET-CT
For
18 F-FDG PET-CT examination, patients are required
to fast at least 6 hours prior to the application. Diabetes
mellitus should be treated properly in advance but the use
of insulin is not allowed. The radiopharmaceutical
18 F-
FDG is given intravenously (i.v.). Administered activity is
estimated between 3.5 and 5 MBq/kg of bodyweight. If
there are no contraindications, 20 to 40 mg butylscopola-
miniumbromide will be administered i.v. to reduce bowel
movement and therefore the physiological glucose uptake.
Bowel distension using water and 10 ml of 10% mannitol
will be performed additionally for oral contrast enhance-
ment. After identification of the tumor using a ultra low
dose scout scan, the tracer substance will be administered
intravenously and a dynamic acquisition over 60 minutes
will start, followed by a whole body scan from head to
upper femur. In addition, a diagnostic routine CT using
intravenous contrast enhancement will be performed after
PET acquisition at baseline. SUVs will be used for quanti-
tative
18 F-FDG PET-CT analysis to evaluate the changes
of glucose metabolism. Using baseline and follow-up
18 F-
FDG PET-CT and the related SUVs, the predictive rele-
vance of the relative changes in SUV for early clinical
response will be evaluated. PET/CT scans will be per-
formed on a SIEMENS PET/CT Biograph 6 (SIEMENS
Healthcare, Erlangen Germany) with an axial field of view
of 15,4 cm in 3D mode. All images will be reconstructed
using OSEM 2D, four iterations and eight subsets. All
image data set is normalized for the injected dose and the-
patients body weight. This results in parametric imaging
using widely accepted standardized uptake value (SUV) on
the basis of the formula “SUV = tissue concentration (Bq/
g)/(injected dose (Bq)/body weight (g))”.
For quantitative evaluation, an automated volume of
interest (VOI) derived from generated regions of interest
(ROI) using the auto3D function within the SYNGO Soft-
ware (Siemens Healthcare Erlangen, Germany) will be
placed over the tumor. In the second PET scan, the region
of interest will be placed at the same position as in the
baseline PET as a reference of initial maximal uptake.
Contrast-enhanced ultrasound (CEUS)
For contrast-enhanced ultrasound, the i.v. application of
2.4 ml SonoVue
® (sulfurhexafluoride-microbubbles) is
necessary. SonoVue
® is approved for ultrasound examina-
tion to improve echogenicityo fb l o o da n dv e s s e ls t r u c -
tures from time-intensity curves obtained during constant
infusion, and using dedicated software for the analysis of
replenishment kinetics. Furthermore, methods have been
developed at the German Cancer Research Center
(Deutsches Krebsforschungszentrum, DKFZ) which
directly measure relative blood volume and perfusion.
Collection and processing of samples
If special written informed consent for translational
research is available, 20 ml of venous blood will be
t a k e na tb a s e l i n ea n do nd a y1 4f o rc y t o k i n ei m m u n e
monitoring during the study. Tumor protein and tumor
gene expression analyses will be performed on the exist-
ing pre-therapeutic biopsy specimen, if available.
Study objectives
The primary objective of this study is to evaluate the
predictive relevance of relative changes in SUV mea-
sured with
18 F-FDG PET-CT during short-term run-in
treatment with the EGFR-mAB cetuximab for the early
Table 1 Folfiri-Cetuximab-regimen, to be repeated every
2 weeks
Chemotherapeutic agent Dosage (mg/m
2) Treatment day
Cetuximab 250 * 1, 8
* 400 at first application
Irinotecan 180 1
Folinic Acid 400 1
5Fluorouracil (bolus) 400 1
5Fluorouracil (46 hours) 2400 1
Table 2 Flowchart (diagnostic procedures and run-in
treatment)
Baseline Day 1 Day 8 Day 14 Day 56
PET-CT Cetuximab Cetuximab PET-CT Folfiri-Cetuximab CT
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neither aimed at demonstrating an increase in the early
clinical response rate compared to an assumed rate of a
conventional treatment, nor to show that the early clini-
cal response rate of the study treatment is higher than a
given „uninteresting” rate. The trial’s secondary objec-
t i v e sa r et h ed u r a t i o no fP F Sa n dO Sa sw e l la st h e
influence of changes in individual SUV and early clinical
response on PFS and OS, respectively. Additionally, for
patients with liver metastases there is an assessment of
antivascular/antiangiogenic effects of cetuximab by con-
trast-enhanced ultrasound on baseline and day 14. The
clinical trial includes an accompanying research pro-
gram involving collection of biological samples for pseu-
donymized analyses. These comprise sequential serum
protein marker assessments (like multiplex cytokine
immune monitoring) as well as baseline analysis of
tumor proteins and tumor genes. Patients can partici-
pate in this study even if they choose not to participate
in this translational research program.
Trial population
Patients with untreated metastatic colorectal cancer can
participate in the REMOTUX trial when the eligibility cri-
teria are met. Those criteria include histologically con-
firmed metastatic colorectal cancer with a KRAS-wildtype
status of the tumor and no history of previous therapy
with an EGFR-targeting agent or previous chemotherapy
for advanced disease. Patients must have an adequate
hematologic, renal and hepatic function and must be able
to undergo chemotherapy according to the Folfiri regimen.
Patients with an ECOG-performance status less than 1,
CNS metastases or an uncontrolled diabetes mellitus can
not participate in the study. For imaging, there must be at
least one measurable tumor lesion with a diameter no
smaller than 1.0 cm detected by CT, MRI or ultrasound
and for contrast-enhanced ultrasound the liver metastases
must not be smaller than 2.0 cm. The detailed criteria are
shown in Table 3.
Statistical considerations
Study hypothesis
The main hypothesis to be tested in the primary analysis
is whether or not the relative change
(ΔSUV = 100⋅(SUVBaseline-SUVd14)/SUVBaseline)i nt h e
SUV from baseline to day 14 has any predictive relevance
for early clinical response determined at day 56. This
hypothesis is tested by comparing the groups of early
clinical responders and nonresponders with respect to
the quantitative variable ΔSUV using a Wilcoxon rank
sum test (2-sided test, a = 5%)
Sample size calculation
The trial will include 35 patients who are evaluable for
the primary analysis. The sample size/power calculations
were based on the Wilcoxon rank sum test (two-sided
testing; a = 5%) in the form proposed by Noether [13]
and implemented in the software package nquery advi-
sor 6.01 [Statistical Solutions, Inc.: nquery advisor
® 6.01.
Saugus, MA (2005)]. This form of the power calculation
assumes that the alternative hypothesis is expressed as a
probability P(Y > X), which, in our context, is the prob-
ability that a random responder has a higher value of
ΔSUV than a random nonresponder. Note that the
probability P(Y > X) is identical to the AUC of the
population ROC of ΔSUV with respect to the binary
r e s p o n s e .I ts h o u l db eo b s e r v e dt h a tt h eg r o u ps i z e so f
this test cannot be determined in advance. Rather, the
number of responders follows a binomial distribution
with n = number of evaluable patients, and binomial
probability r = probability of response. Therefore, the
power of the test is a weighted sum of the values of the
power calculated for each possible constellation of
group sizes of responders and nonresponders, the
weights being the binomial probabilities that a particular
constellation arises. Assuming that the values of ΔSUV
in the groups of clinical responders and nonresponders,
resp., are represented by independent normally distribu-
ted variables with equal variances, and assuming that
the true early clinical response rate of r is in the range
40% to 60%, the projected sample size of 35 evaluable
patients is sufficient to detect an AUC of ΔSUV (calcu-
lated with respect to response) of 0.8 with power 84.1%
(the maximum power of 85.7% being attained for r =
50%). It should be noted, however, that the true clinical
response rate r is unknown. For r = 65% (instead of r =
60%) the estimated power for an AUC = 0.8 drops to
81.9%. Therefore, the slight overpowering if r is in the
assumed range of values (40% to 60%) appears justified.
Assuming that about 10% of the enrolled patients are
not evaluable for the primary analysis, it is expected that
the total number of patients to be enrolled in the study
is 39. It is noteworthy that, under the assumptions spe-
cified above, 35 evaluable patients are also sufficient for
detecting with power > 80% an AUC of 0.8 in the
exploratory analysis of the main end point by means of
a univariate logistic regression analysis (calculations
based on 10000 computer simulations runs).
Statistical analysis
The null hypothesis that ΔSUV has no predictive power
for early response will be tested using the Wilcoxon rank
sum test (2-sided test, a = 5%). The null hypothesis of
this test is that the distributions of ΔSUV in the groups
of early clinical responders and nonresponders are identi-
cal. The AUC of ΔSUV with respect to the response sta-
tus will be calculated along with bias-corrected and
accelerated bootstrap 95% confidence intervals, as
described by Zhou [14]. If, based on the results, a cut-off
for predicting response is selected post hoc, then using
Berger et al. BMC Cancer 2012, 12:108
http://www.biomedcentral.com/1471-2407/12/108
Page 4 of 6the bootstrap (and with the same criterion as used in the
selection) bias-corrected indices of accuracy will be esti-
mated from the data. Logistic regression models will be
used to further explore the relationship between ΔSUV
and early clinical response, and, in particular, whether
any confounder for the relationship between ΔSUV and
early clinical response can be determined. The model
assumption of a linear relationship between ΔSUV and
the logit of endpoint will be explored by visual inspec-
tion. Standard methods for right-censored data will be
used for analyzing PFS and OS. The Cox Regression
model will be used to examine the influence of ΔSUV
and of early clinical response on PFS and OS. For the
evaluation of the predictive value of ΔSUV for clinical
tumor response all patients will be analyzed for whom
the variable ΔSUV as well as the response measurement
is available. The assessment of safety will be based mainly
on the frequency of adverse events and on the number of
laboratory values that fall outside of pre-determined
ranges and/or show prominent worsening from baseline
during the study phase. Missing values will not be
replaced or imputed
Safety aspects and adverse events (AEs)
Due to the use of a safe and well known therapeutic regi-
men, there are only few AEs to be expected. Skin toxicity
≤ grade 3 caused by cetuximab will not be reported as an
AE. In this trial, all AEs that occur after the patient has
signed the informed consent document will be documen-
ted. All patients who have AEs, whether considered asso-
ciated with the use of the trial medication or not, are
monitored to determine the outcome. The clinical course
of the AE will be followed-up until resolution or normali-
zation of changed laboratory parameters or until it has
changed to a stable condition.
Current status
At the time of writing we have included 7 patients. The
recruitment period is expected to last 12 more months.
Evaluation of the clinical data will be done within three
months after inclusion of the last patients. There is no
planned interim analysis.
Discussion
Given the increasing costs of modern oncologic treat-
ment [15] and the possible toxicities of anticancer
drugs, refinements to the use of modern therapeutic
agents and therapy strategies are essential to improve
oncologic care. For the use of cetuximab, it is already
known that effectiveness is restricted to patients with a
wild-type KRAS status. Still, a subgroup of these
patients does not respond to cetuximab therapy and
additional methods for identifying responders in advance
are requested.
18 F-FDG PET-CT has demonstrated its
value in the early assessment of metabolic response in
localized cancer of esophagogastric junction during
neoadjuvant combination chemotherapy. Additionally, it
was demonstrated to predict clinical outcome in
advanced gastric cancer during combination therapy
with Folfiri and cetuximab [16] but tumor metabolism
has not been analyzed in terms of single agent treatment
with an EGFR mAB.
Our study was designed to evaluate metabolic response
during run-in single agent therapy with cetuximab in cor-
relation with clinical response. To our knowledge, this is
the first analysis concerning the question of changes in
tumor glucose metabolism and tumor vascularization
under single-agent cetuximab in solid tumors. If there
are measureable metabolic changes, their correlation
with clinical response will be most interesting. In case of
positive correlation, further studies could answer the
Table 3 Detailed inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
￿ Histologically confirmed metastatic colorectal cancer
￿ KRAS-wildtype status of the tumor
￿ No history of therapy with an EGFR targeting agent
￿ No history of previous chemotherapy for advanced disease
￿ Measurable tumor lesion with a diameter no smaller than 1.0 cm
detected by CT, MRIor ultrasound
￿ For contrast-enhanced ultrasound: metastases no smaller than 2.0
cm detected by ultrasound
￿ ECOG-performance status 0 or 1 or Karnofsky performance scale
min. 70%
￿ Life expectancy > 12 weeks
￿ Age ≥ 18 years
￿ Adequate hematologic, renal and hepatic function
￿ Ability of the patient to understand the character and individual
consequences of this clinical trial
￿ Written informed consent (must be available before enrolment in
the trial)
￿ For women and men with childbearing potential adequate double
barrier contraception, for women: negative pregnancy test
￿ Any contraindications for chemotherapy according to the Folfiri regimen
￿ Non-curatively treated malignancy within the last 5 years
￿ Uncontrolled or insulin-dependant diabetes mellitus
￿ Evidence of CNS metastases
￿ Uncontrolled infection
￿ Significant cardiac disease (unstable angina pectoris or cardiac symptoms
according to NYHA classification III or IV)
￿ Active serious illness which renders the patient unsuitable for study entry or
multiple blood sampling
￿ Pregnancy and lactation
￿ History of hypersensitivity to cetuximab or to any drug with similar chemical
structure or to any excipient present in the pharmaceutical form of the
investigational medicinal product
￿Participation in other clinical trials or observation period of competing trials,
respectively
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responding to cetuximab is possible to avoid unnecces-
sary toxic and cost-intensive treatment.
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